Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)

Overview

Journal Circulation

Specialty Cardiology & Vascular Diseases

Date 2015 Oct 30

PMID 26510696

Citations 61

Authors

Ioana R Preston

Kari E Roberts

Dave P Miller

Ginny P Sen

Mona Selej

Wade W Benton

Nicholas S Hill

Harrison W Farber

Affiliations

Soon will be listed here.

Abstract

Background: Long-term anticoagulation is recommended in idiopathic pulmonary arterial hypertension (IPAH). In contrast, limited data support anticoagulation in pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc-PAH). We assessed the effect of warfarin anticoagulation on survival in IPAH and SSc-PAH patients enrolled in Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL), a longitudinal registry of group I PAH.

Methods And Results: Patients who initiated warfarin on study (n=187) were matched 1:1 with patients never on warfarin, by enrollment site, etiology, and diagnosis status. Descriptive analyses were conducted to compare warfarin users and nonusers by etiology. Survival analyses with and without risk adjustment were performed from the time of warfarin initiation or a corresponding quarterly update in matched pairs to avoid immortal time bias. Time-varying covariate models were used as sensitivity analyses. Mean warfarin treatment was 1 year; mean international normalized ratios were 1.9 (IPAH) and 2.0 (SSc-PAH). Two-thirds of patients initiating warfarin discontinued treatment before the last study assessment. There was no survival difference with warfarin in IPAH patients (adjusted hazard ratio, 1.37; P=0.21) or in SSc-PAH patients (adjusted hazard ratio, 1.60; P=0.15) in comparison with matched controls. However, SSc-PAH patients receiving warfarin within the previous year (hazard ratio, 1.57; P=0.031) or any time postbaseline (hazard ratio, 1.49; P=0.046) had increased mortality in comparison with warfarin-naïve patients.

Conclusions: No significant survival advantage was observed in IPAH patients who started warfarin. In SSc-PAH patients, long-term warfarin was associated with poorer survival than in patients not receiving warfarin, even after adjusting for confounders.

Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00370214.

Citing Articles

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies.

Tsai J, Malik S, Tjen-A-Looi S Life (Basel). 2024; 14(10).

PMID: 39459565 PMC: 11509317. DOI: 10.3390/life14101265.

Circulating extracellular vesicles as novel biomarkers for pulmonary arterial hypertension in patients with systemic lupus erythematosus.

Ding Z, Qi F, Liu L, Wang Z, Zhang N, Lyu X Front Immunol. 2024; 15:1374100.

PMID: 39364410 PMC: 11446868. DOI: 10.3389/fimmu.2024.1374100.

Treatment algorithm for pulmonary arterial hypertension.

Chin K, Gaine S, Gerges C, Jing Z, Mathai S, Tamura Y Eur Respir J. 2024; 64(4).

PMID: 39209476 PMC: 11525349. DOI: 10.1183/13993003.01325-2024.

Cardiac Arrhythmias in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Mechanistic Insights, Pathophysiology, and Outcomes.

Abouzaid A, Ali K, Jatoi S, Ahmed M, Ahmad G, Nazim A Ann Noninvasive Electrocardiol. 2024; 29(5):e70010.

PMID: 39205610 PMC: 11358588. DOI: 10.1111/anec.70010.

Long-term efficacies of selective vasodilators in pulmonary arterial hypertension: a comprehensive comparison using a spontaneous reporting database.

Suzuki K, Yagi T, Kawakami J Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):4981-4992.

PMID: 38180559 DOI: 10.1007/s00210-023-02929-0.

References

Galie N, Simonneau G . The Fifth World Symposium on Pulmonary Hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D1-3. DOI: 10.1016/j.jacc.2013.10.030. View

McGoon M, Benza R, Escribano-Subias P, Jiang X, Miller D, Peacock A . Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013; 62(25 Suppl):D51-9. DOI: 10.1016/j.jacc.2013.10.023. View

Haddad F, Spruijt O, Denault A, Mercier O, Brunner N, Furman D . Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2015; 8(6):627-38. PMC: 4466029. DOI: 10.1016/j.jcmg.2014.12.029. View

Galie N, Corris P, Frost A, Girgis R, Granton J, Jing Z . Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D60-72. DOI: 10.1016/j.jacc.2013.10.031. View

Sitbon O, Benza R, Badesch D, Barst R, Elliott C, Gressin V . Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J. 2015; 46(1):152-64. DOI: 10.1183/09031936.00004414. View

Hirsh J, Fuster V, Ansell J, Halperin J . American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003; 107(12):1692-711. DOI: 10.1161/01.CIR.0000063575.17904.4E. View

STORSTEIN O, EFSKIND L, Muller C, ROKSETH R, Sander S . Primary pulmonary hypertension with emphasis on its etiology and treatment. Acta Med Scand. 1966; 179(2):197-212. DOI: 10.1111/j.0954-6820.1966.tb05449.x. View

Wagenvoort C . Vasoconstrictive primary pulmonary hypertension and pulmonary veno-occlusive disease. Cardiovasc Clin. 1972; 4(2):97-113. View

Wagenvoort C, WAGENVOORT N . Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv Cardiol. 1974; 11(00):123-30. DOI: 10.1159/000395210. View

10.

Fuster V, Steele P, Edwards W, Gersh B, McGoon M, Frye R . Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984; 70(4):580-7. DOI: 10.1161/01.cir.70.4.580. View

11.

Rich S, Kaufmann E, LEVY P . The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327(2):76-81. DOI: 10.1056/NEJM199207093270203. View

12.

Ogata M, Ohe M, Shirato K, Takishima T . Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn Circ J. 1993; 57(1):63-9. DOI: 10.1253/jcj.57.63. View

13.

Frank H, Mlczoch J, Huber K, Schuster E, GURTNER H, Kneussl M . The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997; 112(3):714-21. DOI: 10.1378/chest.112.3.714. View

14.

Hoeper M, Sosada M, FABEL H . Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J. 1999; 12(6):1446-9. DOI: 10.1183/09031936.98.12061446. View

15.

Kawut S, Horn E, Berekashvili K, Garofano R, Goldsmith R, Widlitz A . New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol. 2005; 95(2):199-203. DOI: 10.1016/j.amjcard.2004.09.006. View

16.

Garcia D, Regan S, Crowther M, Hylek E . The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006; 47(4):804-8. DOI: 10.1016/j.jacc.2005.09.058. View

17.

Johnson S, Granton J, Mehta S . Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest. 2006; 130(2):545-52. DOI: 10.1378/chest.130.2.545. View

18.

McLaughlin V, McGoon M . Pulmonary arterial hypertension. Circulation. 2006; 114(13):1417-31. DOI: 10.1161/CIRCULATIONAHA.104.503540. View

19.

Badesch D, Abman S, Simonneau G, Rubin L, McLaughlin V . Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007; 131(6):1917-28. DOI: 10.1378/chest.06-2674. View

20.

Suissa S . Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008; 168(3):329-35. DOI: 10.1093/aje/kwn135. View